Home › Companies › Kura Oncology, Inc. › 2025-2026

Kura Oncology, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Kura Oncology, Inc.’s Form 8-K, filed 2026-06-04 (Item 5.07 on EDGAR). Page generated 04 October 2026.

8Reported items
201Asset managers
1,795Fund votes
2026-06-04Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Kura Oncology, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Kura Oncology, Inc.

These tallies are Kura Oncology, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Kura Oncology, Inc. — official shareholder meeting results, meeting held 2026-06-04
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Diane Parks	44,060,724	--	--	14,620,308	11,097,548	Majority: yes
Elect Director: Mary T. Szela	38,859,502	--	--	19,821,530	11,097,548	Majority: yes
Elect Director: Michael J. Vasconcelles, M.D.	58,169,894	--	--	511,138	11,097,548	Majority: yes
Proposal 2. Ratification of the Appointment of Independent Registered Public Accounting Firm	69,385,497	140,763	252,320	--	--	Majority: yes
Proposal 3. Advisory Vote on Executive Compensation	48,783,834	1,141,854	8,755,344	--	11,097,548	Majority: yes
Proposal 4. Advisory Indication on Frequency of Stockholder Advisory Votes on Executive Compensation	48,402,820	10,099,296	178,916	--	11,097,548	Majority: yes
Proposal 6. Approval of our Amended ESPP	58,306,174	213,434	161,424	--	11,097,548	Majority: yes

Source: Kura Oncology, Inc., Form 8-K, filed with the SEC on 2026-06-04 — read the filing on EDGAR.

How asset managers voted at the Kura Oncology, Inc. 2025-2026 meeting

Each item below shows how the 201 asset managers that disclosed a Kura Oncology, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Kura Oncology, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, on an advisory basis, of the compensation of our named executive officers ("Say-on-Pay"), as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 48,783,834AGAINST: 1,141,854

Kura Oncology, Inc.’s own tally for this item (“Proposal 3. Advisory Vote on Executive Compensation”): 48,783,834 for, 1,141,854 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,774,365 outstanding shares: 55.0% for, 1% against (56% of the company cast a for/against vote).

The 201 asset managers below cast 97% of the shares they voted on this item FOR (43,777,265 for, 1,281,733 against).

FOR 82%ABSTAIN 16%

FOR: 43,777,265 (81.8%)AGAINST: 1,281,733 (2.4%)ABSTAIN: 8,481,641 (15.8%)NOT VOTED: 8,445 (0.0%)OTHER. SEE OTHER INFORMATION COLUMN: 174 (0.0%)

Largest asset managers voting on “Approval, on an advisory basis, of the compensation of our named executive officers ("Say-on-Pay"), as disclos” at Kura Oncology, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
BVF INC/IL	0	0	8,445,769	Abstain
BlackRock	6,301,926	50,658	0	For
MONTANOVA CAPITAL, LLC	6,267,394	0	0	For
Vanguard	5,649,640	1	22	For
State Street	4,210,957	14,848	0	For
Fidelity	2,447,834	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,034,276	0	0	For
Deep Track Capital, LP	1,885,890	0	0	For
Charles Schwab	1,382,213	0	0	For
NAN FUNG TRINITY (HK) Ltd	1,064,880	0	0	For
AQR	984,291	0	0	For
1492 Capital Management LLC	927,625	0	0	For
American Century	0	855,903	0	Against
Logos Global Management LP	751,331	0	0	For
Northern Trust	661,047	13,736	0	For
Dimensional	631,172	0	0	For
Invesco	585,303	0	0	For
Renaissance	549,885	0	0	For
Fisher Asset Management, LLC	538,715	0	0	For
Prosight Management, LP	467,379	0	0	For
ARMISTICE CAPITAL, LLC	433,193	0	0	For
GREAT LAKES ADVISORS, LLC	339,207	0	0	For
SECTOR GAMMA AS	324,503	0	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	282,045	0	0	For
Nationwide	248,813	0	0	For

Showing the 25 largest of 201 asset managers. See all 201 in the interactive database.

2. INDICATION, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF HOLDING FUTURE SAY-ON-PAY VOTES ON EXECUTIVE COMPENSATION.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%AGAINST 17%

FOR: 48,402,820AGAINST: 10,099,296

Kura Oncology, Inc.’s own tally for this item (“Proposal 4. Advisory Indication on Frequency of Stockholder Advisory Votes on Executive Compensation”): 48,402,820 for, 10,099,296 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,774,365 outstanding shares: 54.5% for, 11% against (66% of the company cast a for/against vote).

The 196 asset managers below cast 100% of the shares they voted on this item FOR (35,179 for, 0 against).

ABSTAIN 16%ONE YEAR 56%1 YEAR 25%

FOR: 35,179 (0.1%)ABSTAIN: 8,460,636 (16.0%)ONE YEAR: 29,632,111 (56.2%)1 YEAR: 13,206,272 (25.0%)1-YEAR: 751,331 (1.4%)THREE YEARS: 644,065 (1.2%)3 YEARS: 23,139 (0.0%)NOT VOTED: 8,445 (0.0%)1.0: 116 (0.0%)3.0: 4 (0.0%)

Largest asset managers voting on “INDICATION, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF HOLDING FUTURE SAY-ON-PAY VOTES ON EXECUTIVE C” at Kura Oncology, Inc., 2025-2026
Asset manager	Abstain	Vote
BVF INC/IL	8,445,769	Abstain
BlackRock	0	1 Year
MONTANOVA CAPITAL, LLC	0	One Year
Vanguard	22	One Year
State Street	0	One Year
Fidelity	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	One Year
Deep Track Capital, LP	0	1 Year
Charles Schwab	0	1 Year
NAN FUNG TRINITY (HK) Ltd	0	One Year
AQR	0	One Year
American Century	0	One Year
Logos Global Management LP	0	1-Year
Northern Trust	0	1 Year
Dimensional	0	Three Years
Invesco	0	One Year
Renaissance	0	One Year
Fisher Asset Management, LLC	0	One Year
1492 Capital Management LLC	0	1 Year
Prosight Management, LP	0	1 Year
ARMISTICE CAPITAL, LLC	0	1 Year
GREAT LAKES ADVISORS, LLC	0	One Year
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	One Year
Nationwide	0	One Year
Connor, Clark & Lunn Investment Management Ltd.	0	One Year

Showing the 25 largest of 196 asset managers. See all 196 in the interactive database.

3. APPROVAL OF AN AMENDMENT TO OUR 2015 EMPLOYEE STOCK PURCHASE PLAN.

COMPENSATION

99.8% fund support · no official result

FOR 99.8%

The 57 asset managers below cast 99.8% of the shares they voted on this item FOR (15,945,464 for, 30,445 against).

FOR: 15,945,464 (99.8%)AGAINST: 30,445 (0.2%)

Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO OUR 2015 EMPLOYEE STOCK PURCHASE PLAN.” at Kura Oncology, Inc., 2025-2026
Asset manager	For	Vote
Vanguard	4,973,115	For
State Street	2,764,063	For
BlackRock	2,312,210	For
Fidelity	2,128,206	For
Charles Schwab	690,994	For
Dimensional	474,849	For
American Century	412,978	For
Nationwide	248,813	For
Columbia Threadneedle	202,450	For
Equitable	174,355	For
TIAA	148,083	For
QUANTITATIVE MASTER SERIES LLC	137,018	For
GuideStone	135,479	For
Invesco	132,714	For
MASTER INVESTMENT PORTFOLIO	83,422	For
ETFis Series Trust I	82,610	For
Goldman Sachs	75,398	For
ProShares	75,304	For
ALPS ETF Trust	71,906	For
Northern Trust	60,062	For
Lincoln Financial	57,164	For
Harbor ETF Trust	55,530	For
AIG/SunAmerica	40,938	For
Direxion Shares ETF Trust	38,265	For
Global X	37,586	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

4. APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN.

COMPENSATION

83% fund support · no official result

FOR 83%AGAINST 17%

The 57 asset managers below cast 83% of the shares they voted on this item FOR (13,196,998 for, 2,759,123 against).

FOR: 13,196,998 (82.6%)AGAINST: 2,759,123 (17.3%)ABSTAIN: 19,788 (0.1%)

Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN.” at Kura Oncology, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	4,965,776	7,339	For
State Street	2,757,189	6,874	For
BlackRock	2,312,210	0	For
Fidelity	1,819,898	308,308	For
Charles Schwab	690,994	0	For
Dimensional	0	474,849	Against
American Century	0	412,978	Against
Nationwide	26,260	222,553	Against
Columbia Threadneedle	0	202,450	Against
Equitable	117,655	56,700	For
TIAA	0	148,083	Against
QUANTITATIVE MASTER SERIES LLC	137,018	0	For
GuideStone	0	135,479	Against
Invesco	0	132,714	Against
MASTER INVESTMENT PORTFOLIO	83,422	0	For
ETFis Series Trust I	0	82,610	Against
Goldman Sachs	0	75,398	Against
ProShares	0	75,304	Against
ALPS ETF Trust	0	71,906	Against
Northern Trust	0	60,062	Against
Lincoln Financial	55,399	1,765	For
Harbor ETF Trust	55,530	0	For
AIG/SunAmerica	0	40,938	Against
Direxion Shares ETF Trust	0	38,265	Against
Global X	37,586	0	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

5. Election of three Class III directors for three-year terms: Diane Parks

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%WITHHELD 25%

FOR: 44,060,724WITHHELD: 14,620,308

Kura Oncology, Inc.’s own tally for this item (“Elect Director: Diane Parks”): 44,060,724 for, 14,620,308 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,774,365 outstanding shares: 49.6% for, 16% withheld (66% of the company cast a for/withheld vote).

The 57 asset managers below cast 100% of the shares they voted on this item FOR (10,505,118 for, 0 against).

FOR 66%ABSTAIN 34%

FOR: 10,505,118 (65.8%)ABSTAIN: 5,470,792 (34.2%)

Largest asset managers voting on “Election of three Class III directors for three-year terms: Diane Parks” at Kura Oncology, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	4,962,253	10,862	For
State Street	2,070	2,761,993	Abstain
BlackRock	2,312,210	0	For
Fidelity	2,128,206	0	For
Charles Schwab	0	690,994	Abstain
Dimensional	0	474,849	Abstain
American Century	0	412,978	Abstain
Nationwide	22,025	226,788	Abstain
Columbia Threadneedle	202,450	0	For
Equitable	117,655	56,700	For
TIAA	148,083	0	For
QUANTITATIVE MASTER SERIES LLC	137,018	0	For
GuideStone	0	135,479	Abstain
Invesco	132,714	0	For
MASTER INVESTMENT PORTFOLIO	83,422	0	For
ETFis Series Trust I	0	82,610	Abstain
Goldman Sachs	75,398	0	For
ProShares	0	75,304	Abstain
ALPS ETF Trust	0	71,906	Abstain
Northern Trust	0	60,062	Abstain
Lincoln Financial	0	57,164	Abstain
Harbor ETF Trust	55,530	0	For
AIG/SunAmerica	0	40,938	Abstain
Direxion Shares ETF Trust	0	38,265	Abstain
Global X	0	37,586	Abstain

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

6. Election of three Class III directors for three-year terms: Mary T. Szela

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

66% Majority: yes · of votes cast

FOR 66%WITHHELD 34%

FOR: 38,859,502WITHHELD: 19,821,530

Kura Oncology, Inc.’s own tally for this item (“Elect Director: Mary T. Szela”): 38,859,502 for, 19,821,530 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,774,365 outstanding shares: 44% for, 22% withheld (66% of the company cast a for/withheld vote).

The 57 asset managers below cast 100% of the shares they voted on this item FOR (8,220,993 for, 0 against).

FOR 51.5%ABSTAIN 48.5%

FOR: 8,220,993 (51.5%)ABSTAIN: 7,754,916 (48.5%)

Largest asset managers voting on “Election of three Class III directors for three-year terms: Mary T. Szela” at Kura Oncology, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	4,962,240	10,875	For
State Street	2,756,416	7,647	For
BlackRock	0	2,312,210	Abstain
Fidelity	0	2,128,206	Abstain
Charles Schwab	0	690,994	Abstain
Dimensional	0	474,849	Abstain
American Century	0	412,978	Abstain
Nationwide	0	248,813	Abstain
Columbia Threadneedle	0	202,450	Abstain
Equitable	0	174,355	Abstain
TIAA	148,083	0	For
QUANTITATIVE MASTER SERIES LLC	0	137,018	Abstain
GuideStone	0	135,479	Abstain
Invesco	132,714	0	For
MASTER INVESTMENT PORTFOLIO	0	83,422	Abstain
ETFis Series Trust I	0	82,610	Abstain
Goldman Sachs	75,398	0	For
ProShares	0	75,304	Abstain
ALPS ETF Trust	0	71,906	Abstain
Northern Trust	0	60,062	Abstain
Lincoln Financial	55,399	1,765	For
Harbor ETF Trust	55,530	0	For
AIG/SunAmerica	0	40,938	Abstain
Direxion Shares ETF Trust	0	38,265	Abstain
Global X	0	37,586	Abstain

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

7. Election of three Class III directors for three-year terms: Michael J. Vasconcelles, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 58,169,894WITHHELD: 511,138

Kura Oncology, Inc.’s own tally for this item (“Elect Director: Michael J. Vasconcelles, M.D.”): 58,169,894 for, 511,138 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,774,365 outstanding shares: 66% for, 0.6% withheld (66% of the company cast a for/withheld vote).

The 57 asset managers below cast 100% of the shares they voted on this item FOR (15,904,363 for, 0 against).

FOR 99.5%

FOR: 15,904,363 (99.6%)ABSTAIN: 71,546 (0.4%)

Largest asset managers voting on “Election of three Class III directors for three-year terms: Michael J. Vasconcelles, M.D.” at Kura Oncology, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	4,973,114	1	For
State Street	2,764,063	0	For
BlackRock	2,312,210	0	For
Fidelity	2,128,206	0	For
Charles Schwab	690,994	0	For
Dimensional	474,849	0	For
American Century	412,978	0	For
Nationwide	248,813	0	For
Columbia Threadneedle	202,450	0	For
Equitable	117,655	56,700	For
TIAA	148,083	0	For
QUANTITATIVE MASTER SERIES LLC	137,018	0	For
GuideStone	135,479	0	For
Invesco	132,714	0	For
MASTER INVESTMENT PORTFOLIO	83,422	0	For
ETFis Series Trust I	82,610	0	For
Goldman Sachs	75,398	0	For
ProShares	75,304	0	For
ALPS ETF Trust	71,906	0	For
Northern Trust	60,062	0	For
Lincoln Financial	57,164	0	For
Harbor ETF Trust	55,530	0	For
AIG/SunAmerica	40,938	0	For
Direxion Shares ETF Trust	38,265	0	For
Global X	37,586	0	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

8. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

99.7% Majority: yes · of votes cast

FOR 99.7%

FOR: 69,385,497AGAINST: 140,763

Kura Oncology, Inc.’s own tally for this item (“Proposal 2. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 69,385,497 for, 140,763 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,774,365 outstanding shares: 78% for, 0.2% against (78% of the company cast a for/against vote).

The 57 asset managers below cast 99.9% of the shares they voted on this item FOR (15,960,954 for, 110 against).

FOR 99.9%

FOR: 15,960,954 (99.9%)AGAINST: 110 (0.0%)ABSTAIN: 14,845 (0.1%)

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at Kura Oncology, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	4,973,115	0	For
State Street	2,763,953	110	For
BlackRock	2,312,210	0	For
Fidelity	2,128,206	0	For
Charles Schwab	690,994	0	For
Dimensional	474,849	0	For
American Century	412,978	0	For
Nationwide	248,813	0	For
Columbia Threadneedle	202,450	0	For
Equitable	174,355	0	For
TIAA	148,083	0	For
QUANTITATIVE MASTER SERIES LLC	137,018	0	For
GuideStone	135,479	0	For
Invesco	132,714	0	For
MASTER INVESTMENT PORTFOLIO	83,422	0	For
ETFis Series Trust I	82,610	0	For
Goldman Sachs	75,398	0	For
ProShares	75,304	0	For
ALPS ETF Trust	71,906	0	For
Northern Trust	60,062	0	For
Lincoln Financial	57,164	0	For
Harbor ETF Trust	55,530	0	For
AIG/SunAmerica	40,938	0	For
Direxion Shares ETF Trust	38,265	0	For
Global X	37,586	0	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

Largest Kura Oncology, Inc. shareholders voting in 2025-2026

Ranked by the number of Kura Oncology, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 88,774,365 shares outstanding at the time of that meeting.

Top Kura Oncology, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	BVF INC/IL	9.51%
2	BlackRock	7.16%
3	MONTANOVA CAPITAL, LLC	7.06%
4	Vanguard	6.36%
5	State Street	4.76%
6	Fidelity	2.76%
7	GEODE CAPITAL MANAGEMENT, LLC	2.29%
8	Deep Track Capital, LP	2.12%
9	Charles Schwab	1.56%
10	NAN FUNG TRINITY (HK) Ltd	1.20%

Reported Kura Oncology, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Kura Oncology, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	10.86%	13F
BVF Partners L.P.	9.84%	DEF14A
Montanova Capital, LLC	9.66%	13G
Suvretta Capital Management, LLC	8.52%	DEF14A
Vanguard Group	6.20%	13F
Armistice Capital	5.56%	DEF14A
STATE STREET CORPORATION	5.55%	13G
Troy E. Wilson, Ph.D., J.D.	4.13%	DEF14A
Geode Capital	2.29%	13F
Renaissance Technologies	1.78%	13F

Percentages above are of 88,774,365 shares outstanding, as reported by Kura Oncology, Inc. on its Form 10-Q dated 2026-05-08 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Kura Oncology, Inc.’s 10-Q dated 2026-05-08. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Kura Oncology, Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 201 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,795 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of our named executive officers… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Kura Oncology, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-04.

Kura Oncology, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).